Stemline Therapeutics (STML) Tops Q1 EPS by 8c

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.51), $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Carlyle sees improving exit conditions for "good companies"
• Orthofix International (OFIX) Tops Q2 EPS by 1c; Offers Guidance
• National Retail Properties (NNN) Tops Q2 EPS by 1c; Offers Guidance